Michal Mielnik
Lublin, LU, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 28, 2025
Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pre-treatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor.
Journal: Frontiers in immunology
Published: January 27, 2024
The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients.
Journal: Biomedicines
Published: September 09, 2023
Prognostic factors and clinical characteristics of patients with newly diagnosed non-secretory multiple myeloma in the era of new drugs in "real-world" study: Experiences of the Polish Myeloma Group.
Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University
Published: August 27, 2023
SARS-CoV-2 Seroprevalence in Healthcare Workers before the Vaccination in Poland: Evolution from the First to the Second Pandemic Outbreak.
Journal: International journal of environmental research and public health
Published: January 07, 2022
Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Journal: Cells
Published: December 10, 2021
Expression of CTLA-4 and CD86 Antigens and Epstein-Barr Virus Reactivation in Chronic Lymphocytic Leukemia-Any Link with Known Prognostic Factors?
Journal: Cancers
Published: December 03, 2021
Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients.
Journal: British journal of haematology
Published: February 24, 2020
Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen.
Journal: Annals of hematology
Published: June 10, 2019
CTLA-4 Expression Inversely Correlates with Kidney Function and Serum Immunoglobulin Concentration in Patients with Primary Glomerulonephritides.
Journal: Archivum immunologiae et therapiae experimentalis
Published: April 06, 2019
Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients.
Journal: British journal of haematology
Published: February 01, 2019
Last Updated: 09/26/2026